Overview A Study of KHK4827 in Subjects With Palmoplantar Pustulosis Status: Active, not recruiting Trial end date: 2022-10-01 Target enrollment: Participant gender: Summary Evaluation of efficacy and safety of KHK4827 in Subjects with Palmoplantar Pustulosis Phase: Phase 3 Details Lead Sponsor: Kyowa Kirin Co., Ltd.Treatments: Brodalumab